Abstract
The authors administered high-dose chemotherapy with cyclophosphamide, BCNU (carmustine) and VP-16 (etoposide) plus autologous bone marrow transplantation (ABMT) to 22 adult patients with relapsed acute leukemia in second or subsequent remission. The marrow was not treated ex vivo. The long-term, disease-free survival rate was 14%. Comparison of results with other treatments can be difficult because of patient selection biases. The concept of inversion (achievement of a longer remission with salvage therapy than with prior treatments) is proposed to compare treatment results. Three patients remain in complete remission beyond 4 years, with inversions. More intensive cytoreductive regimens will be needed to improve results.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Transplantation*
-
Carmustine / administration & dosage
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Granulocytes
-
Humans
-
Leukemia, Myeloid, Acute / blood
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / therapy*
-
Leukocyte Count
-
Male
-
Middle Aged
-
Platelet Count
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
-
Remission Induction
-
Survival Rate
Substances
-
Etoposide
-
Cyclophosphamide
-
Carmustine